Search research articles
Contact Us
Filters
Showing results (61-70 of 101) with videos related to
Page
of 11
Sort By:
Cancers
|
April 27, 2024
The sGCa Vericiguat Exhibit Cardioprotective and Anti-Sarcopenic Effects through NLRP-3 Pathways: Potential Benefits for Anthracycline-Treated Cancer Patients
Vincenzo Quagliariello, Massimiliano Berretta, Irma Bisceglia, et al.
Frontiers in Cardiovascular Medicine
|
September 26, 2022
Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways
Vincenzo Quagliariello, Margherita Passariello, Annabella Di Mauro, et al.
Frontiers in Cardiovascular Medicine
|
February 6, 2023
Corrigendum: Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways
Vincenzo Quagliariello, Margherita Passariello, Annabella Di Mauro, et al.
European Heart Journal Supplements : Journal of the European Society of Cardiology
|
July 29, 2017
ANMCO/AIOM/AICO Consensus Document on clinical and management pathways of cardio-oncology: executive summary
Luigi Tarantini, Michele Massimo Gulizia, Andrea Di Lenarda, et al.
Giornale Italiano Di Cardiologia (2006)
|
March 14, 2017
[ANMCO/AICO/AIOM Consensus document: Clinical and management pathways in cardio-oncology]
Luigi Tarantini, Michele Massimo Gulizia, Andrea Di Lenarda, et al.
Frontiers in Oncology
|
January 23, 2023
The predictive and prognostic role of metabolic and volume-based parameters of positron emission tomography/computed tomography as non-invasive dynamic biological markers in early breast cancer treated with preoperative systemic therapy
Alessandro Inno, Marta Peri, Monica Turazza, et al.
Journal of Translational Medicine
|
June 23, 2026
Sodium-glucose cotransporter 2 inhibitors in breast cancer patients on endocrine therapy: a targeted strategy to mitigate long-term cardiometabolic risk
Vincenzo Quagliariello, Massimiliano Berretta, Irma Bisceglia, et al.
Giornale Italiano Di Cardiologia (2006)
|
October 2, 2025
[Cardiovascular disease in adult cancer survivors: a new frontier for cardio-oncology]
Andrea Tedeschi, Maria Laura Canale, Alessandra Greco, et al.
Cancers
|
April 14, 2025
In the Era of Cardiovascular-Kidney-Metabolic Syndrome in Cardio-Oncology: From Pathogenesis to Prevention and Therapy
Vincenzo Quagliariello, Massimiliano Berretta, Irma Bisceglia, et al.
International Journal of Molecular Sciences
|
July 29, 2025
PCSK9 Inhibitor Inclisiran Attenuates Cardiotoxicity Induced by Sequential Anthracycline and Trastuzumab Exposure via NLRP3 and MyD88 Pathway Inhibition
Vincenzo Quagliariello, Massimiliano Berretta, Irma Bisceglia, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 101) with videos related to
Sort By:
Page
of 11
Cancers
|
April 27, 2024
The sGCa Vericiguat Exhibit Cardioprotective and Anti-Sarcopenic Effects through NLRP-3 Pathways: Potential Benefits for Anthracycline-Treated Cancer Patients
Vincenzo Quagliariello, Massimiliano Berretta, Irma Bisceglia, et al.
Frontiers in Cardiovascular Medicine
|
September 26, 2022
Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways
Vincenzo Quagliariello, Margherita Passariello, Annabella Di Mauro, et al.
Frontiers in Cardiovascular Medicine
|
February 6, 2023
Corrigendum: Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways
Vincenzo Quagliariello, Margherita Passariello, Annabella Di Mauro, et al.
European Heart Journal Supplements : Journal of the European Society of Cardiology
|
July 29, 2017
ANMCO/AIOM/AICO Consensus Document on clinical and management pathways of cardio-oncology: executive summary
Luigi Tarantini, Michele Massimo Gulizia, Andrea Di Lenarda, et al.
Giornale Italiano Di Cardiologia (2006)
|
March 14, 2017
[ANMCO/AICO/AIOM Consensus document: Clinical and management pathways in cardio-oncology]
Luigi Tarantini, Michele Massimo Gulizia, Andrea Di Lenarda, et al.
Frontiers in Oncology
|
January 23, 2023
The predictive and prognostic role of metabolic and volume-based parameters of positron emission tomography/computed tomography as non-invasive dynamic biological markers in early breast cancer treated with preoperative systemic therapy
Alessandro Inno, Marta Peri, Monica Turazza, et al.
Journal of Translational Medicine
|
June 23, 2026
Sodium-glucose cotransporter 2 inhibitors in breast cancer patients on endocrine therapy: a targeted strategy to mitigate long-term cardiometabolic risk
Vincenzo Quagliariello, Massimiliano Berretta, Irma Bisceglia, et al.
Giornale Italiano Di Cardiologia (2006)
|
October 2, 2025
[Cardiovascular disease in adult cancer survivors: a new frontier for cardio-oncology]
Andrea Tedeschi, Maria Laura Canale, Alessandra Greco, et al.
Cancers
|
April 14, 2025
In the Era of Cardiovascular-Kidney-Metabolic Syndrome in Cardio-Oncology: From Pathogenesis to Prevention and Therapy
Vincenzo Quagliariello, Massimiliano Berretta, Irma Bisceglia, et al.
International Journal of Molecular Sciences
|
July 29, 2025
PCSK9 Inhibitor Inclisiran Attenuates Cardiotoxicity Induced by Sequential Anthracycline and Trastuzumab Exposure via NLRP3 and MyD88 Pathway Inhibition
Vincenzo Quagliariello, Massimiliano Berretta, Irma Bisceglia, et al.
Page
of 11